drugset / Trial / NCT05620914
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.
Timeline
- Start
- 2025-07
- Primary completion
- 2026-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Patritumab deruxtecan | Monoclonal antibody | 5.6 mg/kg | Intravenous |